Abstracts tagged "fibromyalgia and randomized trials"

Abstract Number: 150 • 2017 ACR/ARHP Annual Meeting
Effects of Taping Therapy in the Management of Fibromyalgia: A Randomized Controlled Study
Hae Joo Suh¹ and Sang Tae Choi², ¹Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Fibromyalgia is a medical condition characterized by chronic widespread musculoskeletal pain, accompanied by fatigue, insomnia, cognitive problems, psychiatric symptoms and various somatic symptoms. While…
Abstract Number: 2848 • 2013 ACR/ARHP Annual Meeting
A Randomised Controlled Trial (RCT) of Telephone Delivered Cognitive Behaviour Therapy (tCBT) and Exercise In The Management Of Chronic Widespread Pain (CWP): Identifying Long-Term Outcome and Who Benefits From Which Treatment
Gary J. Macfarlane¹, Marcus Beasley¹, Philip Keeley², Karina Lovell², Philip Hannaford³, Deborah PM Symmons⁴, Steve Woby⁵, Gordon J. Prescott⁶ and The MUSICIAN study team⁷, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²School of Nursing, Midwifery and Health Visiting, University of Manchester, Manchester, United Kingdom, ³Centre for Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁵Pennine Acute Hospital NHS Trust, Manchester, United Kingdom, ⁶Statistics Group, University of Aberdeen, Aberdeen, United Kingdom, ⁷Universities of Manchester and Aberdeen, Manchester and Aberdeen, United Kingdom
Background/Purpose: CWP is challenging for rheumatologists to manage and results from long-term epidemiological studies demonstrate that improvement in symptoms is uncommon. Recent reviews have, however, suggested…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].